Trials / Completed
CompletedNCT04319081
Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors
Multicenter, Observational and Prospective Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors (MEMOGAL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (actual)
- Sponsor
- Jose Seijas Amigo · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective will be to evaluate the changes in the cognitive function in naive patients treated with PCSK9 inhibitors (Alirocumab and Evolocumab) by using the Montreal Cognitive Assesment questionnaire (MOCA). The secondary objectives will be: 1) To evaluate the levels of LDL-cholesterol changes from the beginning to the end of the study 2) To evaluate changes in Quality of Life among the EuroQol EQ-5D-3L questionnaire (it will also be associated to the cognitive function) 3) Assesment of direct costs in medications and outpatients consultations related with the health procedures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PCSK9 inhibitor | Patients are included after PCSK9 inhibitors prescription , at the first dispensation |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2022-12-31
- Completion
- 2023-01-13
- First posted
- 2020-03-24
- Last updated
- 2023-01-17
Locations
12 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04319081. Inclusion in this directory is not an endorsement.